Fish & Aquaculture Vaccines Market Outlook 2035 | Salmon, Tilapia & DNA Vaccines

Aquaculture Vaccines Market Size

The global aquaculture vaccines market was valued at US$500.40 million in 2025 and is projected to reach US$1.02 billion by 2035, growing at a CAGR of 7.4% during 2026-2035.

Aquaculture vaccine economics are fundamentally different from conventional companion-animal vaccination.

The decision concerns thousands or millions of animals sharing the same water environment, exposed to pathogens that can spread rapidly through an intensive production system.

This makes vaccination a production-risk decision.

The value of a vaccine is measured through mortality avoided, harvest biomass protected, feed investment preserved, treatment costs reduced, antibiotic use avoided and production cycles kept on schedule.

The addressable base is also getting larger. FAO's State of World Fisheries and Aquaculture 2026 reports that aquaculture production of aquatic animals surpassed 100 million tonnes for the first time in 2024, reaching 103 million tonnes, equivalent to 53% of total aquatic-animal production. Including algae, global aquaculture reached 141 million tonnes with a value of US$391 billion.

That scale makes infectious-disease prevention increasingly important to global food production.

The strongest established vaccine economics remain in high-value finfish such as Atlantic salmon and trout, where individual fish values justify injectable multivalent vaccination. The next commercial frontier is much larger-volume warm-water aquaculture, including tilapia, pangasius, seabass and other species where vaccines must become easier, cheaper and more scalable to administer.

Key Highlights

• 2025 Market Size: US$500.40 Million
• 2035 Market Value: US$1.02 Billion
• CAGR, 2026-2035: 7.4%
• Largest Vaccine Type: Inactivated Vaccines - 59%
• Largest Administration Route: Injection - 58%
• Fastest-Growing Administration Route: Oral Vaccines
• Largest Disease Category: Bacterial Infections - 55%
• Fastest-Emerging Disease Category: Viral Infections
• Largest Species Revenue Pool: Salmon - 39%
• Tilapia Share: 17%
• Largest Region: North America - 38%
• Second-Largest Region: Europe - 34.8%
• Fastest-Growing Region: Asia-Pacific
• Core Commercial Market: Salmonid vaccination
• Major Expansion Market: Tilapia and warm-water finfish
• Primary Technology Trend: Multivalent and species-specific vaccines
• Next-Generation Opportunity: DNA, recombinant and subunit vaccines
• Mass-Vaccination Opportunity: Oral and immersion delivery
• Major Strategic Driver: Reduced antibiotic dependence
• Major Commercial Gap: Vaccines adapted to lower-value tropical species
• Integrated-Service Trend: Vaccines combined with diagnostics, vaccination equipment and farm-health analytics

The Real Market Is the Cost of an Outbreak Avoided

Aquaculture vaccines should not be evaluated only by price per dose.

Fish farmers commit feed, juveniles, labor, energy, water-management capacity and months of production time before an animal reaches harvest weight.

A severe outbreak near the end of that cycle can therefore destroy substantially more value than the replacement cost of the fish itself.

Vaccination protects that accumulated production investment.

This is particularly important as aquaculture intensifies.

Higher stocking density improves farm economics when fish remain healthy, but it can also accelerate pathogen transmission.

The result is a strong commercial relationship between production intensity and preventive health spending.

Vaccination also has a broader One Health value.

WOAH emphasizes vaccination as an important tool for reducing antimicrobial use and antimicrobial resistance in aquaculture. Its current technical work notes that vaccine adoption remains uneven in small-scale aquaculture because of cold-chain limitations, product access, cost and the lack of vaccines tailored to local species.

This creates two different global vaccine markets.

One is a mature premium market in salmonids.

The second is an underpenetrated mass-market opportunity across tropical and subtropical aquaculture.

Salmon Built the Modern Fish-Vaccine Business

Atlantic salmon remains the commercial foundation of aquaculture vaccination.

Salmon has several characteristics that support vaccine economics.

Individual fish values are high.

Production cycles are long.

Large farms manage substantial biomass.

Diseases such as infectious salmon anaemia, infectious pancreatic necrosis, vibriosis, furunculosis, winter sore and pancreas disease can have major economic consequences.

Injecting fish one by one therefore remains commercially justifiable.

PHARMAQ's current portfolio illustrates the maturity of this market. Its ALPHA JECT range includes multivalent injectable vaccines covering combinations of furunculosis, IPN, ISA, vibriosis, cold-water vibriosis, winter sore and other salmonid disease challenges across Norway, Chile, Canada, Iceland, the UK and other producing markets.

The market has consequently evolved beyond single-pathogen prevention.

A salmon producer increasingly wants to protect one fish against several commercially relevant diseases within one vaccination process.

That reduces handling and makes multivalent formulations more valuable.

Tilapia Could Create the Next Large Volume Market

Tilapia presents almost the opposite commercial challenge.

Global production is large, but individual fish values are substantially lower than premium salmon.

Vaccinating every fish through a labor-intensive injection process can therefore be more difficult to justify.

Disease pressure nevertheless creates a strong need.

Streptococcosis is one of the best-established targets.

PHARMAQ's ALPHA JECT micro 1 Tila targets streptococcosis and is marketed in major Latin American and Asian tilapia-producing countries including Brazil, Colombia, Costa Rica, Honduras, Indonesia and Panama.

MSD Animal Health also operates in warm-water aquaculture, with products such as AQUAVAC Strep SA against Streptococcus agalactiae and AQUAVAC Strep Si against Streptococcus iniae.

The larger market opportunity comes from simplifying delivery.

If oral and immersion platforms can generate durable protection at an acceptable cost, vaccination can penetrate species where individual injection is operationally difficult.

That makes tilapia an important test of whether aquaculture vaccines can move from a premium-fish health category into a mass-production biosecurity tool.

Injection Dominates Because Precision Still Matters

Injection generated an estimated 58% of 2025 revenue, equal to US$290.23 million.

Its leadership is commercially logical.

Each fish receives a known dose.

Vaccines can include oil adjuvants.

Several antigens can be delivered together.

The resulting immune response is generally strong and durable.

Current market research also identifies injection as the largest 2025 route, particularly for high-value salmon and trout.

The weakness is labor and handling.

Fish need to be collected, often anesthetized, vaccinated and returned to the production system.

That creates cost and stress.

Automation reduces some of this disadvantage.

PHARMAQ Fishteq provides equipment for both intraperitoneal and intramuscular vaccination with quality-control functionality, illustrating how vaccination machinery is becoming part of the vaccine ecosystem rather than a separate farm purchase.

The injectable market should therefore remain dominant in high-value species even while oral delivery grows faster.

Oral Vaccination Could Unlock the Largest Untapped Population

Oral vaccines accounted for an estimated 18% of 2025 revenue, equal to US$90.07 million, but represent one of the market's strongest long-term opportunities.

The attraction is scale.

A vaccine delivered through feed does not require a farm to inject every animal.

That lowers labor requirements, reduces fish-handling stress and can make repeated or booster vaccination more practical.

Current market analysis identifies oral vaccination as the fastest-growing administration route for precisely these reasons.

The scientific challenge is substantial.

An oral antigen must survive feed manufacturing, storage, the aquatic environment and digestion long enough to trigger the desired immune response.

This has encouraged research into encapsulation, nanoparticles and other delivery technologies.

WOAH's recent work specifically identifies immersion and oral vaccination as potentially attractive approaches for lower-value fish and early life stages, while noting that field efficacy can remain more variable than injection.

The companies that solve consistency will open a significantly larger commercial market.

Immersion Vaccines Solve the Juvenile-Fish Problem

Immersion accounted for an estimated 24% of 2025 market revenue, equal to US$120.10 million.

The route is particularly useful for smaller fish that are difficult to inject individually.

Fish can be exposed to the vaccine through dip or bath systems, allowing mucosal surfaces such as the gills and skin to encounter the antigen.

HIPRA's ICTHIOVAC portfolio demonstrates the commercial use of this approach.

ICTHIOVAC VR can be administered through immersion or injection for vibriosis in turbot and seabass, while ICTHIOVAC PD and related products provide additional Mediterranean aquaculture applications.

PHARMAQ similarly markets dip vaccines including ALPHA DIP Vib and ALPHA DIP 2000 for Mediterranean species.

Immersion is unlikely to displace injection in large salmon because the commercial priorities differ.

Its strongest role is at the hatchery and juvenile stage, potentially followed later by an injectable booster.

Bacterial Disease Prevention Remains the Revenue Core

Bacterial diseases accounted for an estimated 55% of market revenue in 2025, equal to US$275.22 million.

This position reflects both disease prevalence and vaccine maturity.

Commercial vaccines exist for important pathogens causing vibriosis, furunculosis, streptococcosis, pasteurellosis, yersiniosis, lactococcosis and other bacterial diseases.

Current market research also identifies bacterial applications as the largest segment, citing pathogens such as Aeromonas, Vibrio and Edwardsiella.

Bacterial vaccines have another strategic advantage.

They have demonstrated the ability to reduce antibiotic dependence.

MSD Animal Health notes that after the introduction of vaccination against cold-water vibriosis and furunculosis in Norwegian aquaculture, antibiotic use in fish feed fell dramatically.

This relationship between vaccination and antimicrobial stewardship remains one of the strongest policy supports for the industry.

Viral Vaccines Are Becoming the Innovation Segment

Viral diseases represented an estimated 36% of 2025 market revenue, equal to US$180.14 million.

The category includes infectious salmon anaemia, infectious pancreatic necrosis, viral nervous necrosis and other high-impact diseases.

It is particularly important to next-generation vaccine platforms.

DNA vaccination is attractive because a genetic sequence encoding a target antigen can be introduced without administering the complete pathogen.

Current market research identifies DNA, recombinant, subunit and peptide vaccines as the fastest-developing technology group and specifically cites viral disease targets as important R&D drivers.

Zoetis currently states that its aquaculture R&D is developing DNA vaccines and other new solutions for unmet needs in salmon and tilapia.

HIPRA's ICTHIOVAC VNN provides another commercial example, targeting Viral Nervous Necrosis in seabass.

Viral vaccines are therefore likely to increase their share of market value even while bacterial vaccines remain larger.

Parasitic Vaccines Represent the Hardest Frontier

Parasitic disease and other emerging applications accounted for an estimated 9% of 2025 revenue, equal to US$45.04 million.

Sea lice provide the most commercially important example.

They impose significant welfare and economic costs on salmon farming, but developing effective vaccines against complex parasites is considerably more difficult than producing conventional bacterins.

Current research continues to pursue DNA and recombinant vaccine approaches against sea lice.

If commercially reliable parasite vaccines become available, they could open a new high-value segment because current control often requires mechanical, chemical, biological, or other treatment strategies.

The opportunity is large precisely because vaccine penetration is currently limited.

The Market Is Moving Toward Vaccines + Diagnostics + Administration

The leading companies increasingly sell a health-management platform rather than a vial alone.

PHARMAQ provides vaccines and therapeutics, Fishteq vaccination machinery, and PHARMAQ Analytiq diagnostic services spanning PCR, microbiology, histopathology and next-generation sequencing.

HIPRA combines commercial fish vaccines with diagnostic services, autogenous vaccines, vaccination calculators and farm-data analytics.

MSD Animal Health combines vaccines with aquaculture monitoring and other technology platforms across cold- and warm-water species.

This integration changes competition.

A supplier that detects a farm's pathogen, recommends a vaccination protocol, provides the vaccine, supports administration and monitors outcomes can build a much deeper relationship than a company selling biologicals through distributors alone.

Diagnostics also help address one of the industry's most difficult problems: pathogen variation.

Autogenous Vaccines Are Becoming the Market's Custom-Medicine Layer

Commercial vaccines work best when a common pathogen strain affects a large enough market to justify full product development and registration.

Aquaculture does not always behave that way.

Individual farms can encounter unusual, localized or evolving pathogen strains.

Autogenous vaccines provide a more customized response by using pathogens isolated from a particular farm or epidemiological setting.

The broader global autogenous-vaccine market is expanding partly because commercial vaccines do not always cover localized strains, and aquaculture farms are an important end-user group.

HIPRA currently includes autogenous vaccines alongside its commercial aquaculture portfolio.

This segment should become more relevant as better diagnostics allow producers to identify farm-specific pathogens rapidly.

The commercial model will remain smaller-volume but higher-service-intensity than standard multivalent vaccines.

2026 Signals Showing Where the Market Is Heading

FAO Confirms Aquaculture Has Passed 100 Million Tonnes of Aquatic Animals

SOFIA 2026 reports 103 million tonnes of farmed aquatic animals in 2024, compared with 92 million tonnes from capture fisheries. Aquaculture now supplies 53% of aquatic-animal production globally.

The implication for vaccine companies is structural: the production base requiring disease prevention is still expanding.

India Builds Practical Fish-Vaccination Capability

In July 2026, ICAR-CIBA conducted an intensive five-day program covering injectable, oral and immersion vaccination, recombinant NNV capsid-protein production, vaccine preparation and immune-response monitoring in Asian seabass.

This matters because India is one of the world's largest aquaculture producers but remains relatively underpenetrated by commercial fish vaccines.

Japan Advances Multi-Serotype Yellowtail Vaccination

Kyoritsu Seiyaku highlighted its Pishibac Rensa α3 oil vaccine in June 2026. The vaccine targets all three recognized serotypes of α-haemolytic streptococcosis in yellowtail-related species and is described by the company as the first vaccine covering all three.

Japan's market therefore demonstrates increasing antigen breadth within established aquaculture-vaccine programs.

Zoetis Continues DNA-Vaccine Development for Salmon and Tilapia

Zoetis' current R&D program explicitly identifies DNA vaccines and other innovative aquaculture solutions for salmon and tilapia as active development areas.

This is commercially important because salmon represents today's premium vaccine market while tilapia represents one of the largest future volume opportunities.

WOAH Highlights the Access Gap in Developing Aquaculture

WOAH's current technical review identifies cold chain, affordability, insufficient licensed products and lack of species-specific vaccines as continuing barriers in smaller-scale aquaculture in the Global South.

These barriers explain why the next market cycle depends heavily on scalable oral and immersion platforms.

Aquaculture Vaccines Market Scope

Detailed Market Segmentation

Inactivated Vaccines - 59%

Inactivated vaccines accounted for an estimated 59% of global revenue in 2025, equivalent to US$295.24 million.

They remain the commercial foundation of fish vaccination.

The pathogen is cultured and subsequently inactivated so that it cannot reproduce while retaining antigenic structures capable of stimulating immunity.

This gives inactivated vaccines a favorable safety profile and makes them well suited to multivalent formulations.

The current DataM page also identifies inactivated vaccines as the leading segment.

PHARMAQ's injectable salmon portfolio and HIPRA's ICTHIOVAC products demonstrate the commercial depth of this platform.

The main limitation is that inactivated antigens often require effective adjuvants to sustain immune protection.

This makes adjuvant formulation an important competitive technology rather than a minor product component.

Live Attenuated Vaccines - 13%

Live attenuated vaccines represented an estimated 13% of 2025 revenue, equal to US$65.05 million.

These platforms use weakened organisms capable of producing a strong immune response without causing normal disease under approved conditions.

Their potential advantage is strong and potentially durable immunity.

Their commercial disadvantage is a more complex safety and regulatory profile.

Environmental release and the possibility of reversion require careful evaluation, particularly in open aquatic systems.

Live platforms therefore remain important but smaller than inactivated vaccines.

DNA, Recombinant, Subunit and Other Advanced Vaccines - 28%

Advanced vaccine technologies collectively represented an estimated 28% of market revenue, equal to US$140.11 million.

This group is strategically much more important than its current share suggests.

DNA vaccines allow fish cells to produce selected pathogen antigens.

Recombinant and subunit vaccines focus the immune response on targeted proteins rather than administering the complete organism.

Current external market analysis identifies this advanced category as the fastest-growing vaccine technology segment.

The strongest demand is likely to emerge around viral diseases, emerging pathogens and applications where traditional inactivated vaccines have not delivered sufficient protection.

Zoetis' current aquaculture R&D focus on DNA vaccines strengthens this outlook.

Segmentation by Route of Administration

Injection - 58%

Injectable vaccination generated US$290.23 million in 2025.

The segment is strongest in salmon, trout and other high-value species.

Its commercial advantage is dosage certainty.

A farm knows that each handled fish has received the intended dose.

This allows expensive multivalent formulations to be deployed where disease losses justify the labor cost.

Automatic vaccination equipment is gradually improving economics and quality control, helping injection remain dominant even as other administration routes expand.

Immersion - 24%

Immersion vaccines represented US$120.10 million in 2025.

Their strongest value occurs at hatchery and juvenile stages.

Thousands of small fish can be vaccinated simultaneously without individual injections.

The route also makes use of fish mucosal immunity through the skin and gills.

Its principal commercial limitation is that immunity may be less consistent or shorter-lived than injectable vaccination for some diseases.

This supports combined vaccination strategies where immersion establishes early protection and injection is used later.

Oral Vaccines - 18%

Oral vaccination generated US$90.07 million in 2025 but should gain market share faster than the other routes through 2035.

Its fundamental advantage is labor economics.

Feed can reach very large fish populations simultaneously.

The approach could therefore transform vaccination in tilapia, carp, pangasius and other high-volume species.

The main challenge remains antigen delivery and immune consistency.

If encapsulation and formulation technologies improve sufficiently, oral vaccines could substantially expand the total addressable market rather than simply take share from injection.

Segmentation by Disease

Bacterial Infections - 55%

Bacterial vaccines represented US$275.22 million of 2025 revenue.

The segment includes prevention strategies against vibriosis, furunculosis, streptococcosis, pasteurellosis, lactococcosis, yersiniosis and other economically important diseases.

The wide range of commercially available products makes bacterial disease prevention the most mature market.

The long-term strategic value is strengthened by pressure to reduce antimicrobial use.

Vaccines that prevent a bacterial outbreak do not simply protect biomass; they can also prevent the need for antibiotic treatment.

Viral Infections - 36%

Viral vaccines generated US$180.14 million in 2025.

Growth should exceed the bacterial category as DNA and recombinant technologies mature.

Key targets include ISA, IPN, VNN, iridovirus and other viral diseases capable of causing severe mortality.

MSD's AQUAVAC Irido V and HIPRA's ICTHIOVAC VNN illustrate existing commercial solutions, while next-generation platforms continue to expand the technical opportunity.

Parasitic and Other Diseases - 9%

The remaining US$45.04 million was associated with parasitic and other emerging vaccine applications.

Sea lice remain the category's most important long-term target.

Commercial success against parasites would materially broaden aquaculture vaccination because operators currently spend heavily on non-vaccine control measures.

by Species Economics

Salmon - 39%

Salmon accounted for an estimated 39% of 2025 market revenue, equal to US$195.16 million.

The high value of each fish, advanced farming systems and significant disease exposure support intensive vaccination.

Salmon also has the most developed commercial infrastructure around vaccination machinery, diagnostics and multivalent products.

Norway, Chile, Scotland, Canada, Iceland and the Faroe Islands therefore remain important commercial vaccine markets.

Tilapia - 17%

Tilapia represented US$85.07 million in 2025.

The category's growth potential is substantially greater than its present share because global farm volumes are high.

The critical commercial requirement is lower vaccination cost per fish.

Products targeting streptococcosis already demonstrate the opportunity, but oral and immersion approaches are particularly important for wider adoption.

Trout - 14%

Trout accounted for US$70.06 million.

The species benefits from a relatively mature vaccine ecosystem, particularly in Europe and North America.

Major disease targets include yersiniosis, lactococcosis and bacterial cold-water diseases.

The economics lie between premium salmon and lower-value tropical species, allowing both injection and immersion strategies to remain relevant.

Seabass and Seabream - 15%

Mediterranean seabass and seabream represented an estimated US$75.06 million.

Vibriosis, pasteurellosis and viral nervous necrosis are important commercial disease targets.

HIPRA has developed a particularly strong portfolio around this market, including ICTHIOVAC VR/PD and ICTHIOVAC VNN.

Mediterranean aquaculture therefore provides one of the strongest regional opportunities outside salmonids.

Pangasius and Other Finfish - 15%

Other farmed fish contributed approximately US$75.06 million.

The category contains much of the future Asian volume opportunity.

PHARMAQ already markets ALPHA JECT Panga 2 in Vietnam against enteric septicaemia and motile Aeromonad septicaemia, demonstrating how species-specific commercial vaccines are beginning to penetrate Southeast Asian production.

Regional Market Map

North America - 38%

North America represented an estimated US$190.15 million in 2025, retaining the leading position identified on the current DataM page.

Current external benchmarking similarly places North America at 38.03% of 2025 revenue.

Canada's salmon industry provides the strongest regional commercial vaccine base.

The United States contributes trout, salmonid, catfish and expanding autogenous-vaccine demand.

Regional strengths include sophisticated diagnostics, veterinary infrastructure, established cold chains and the ability of producers to invest in preventative health.

Europe - 34.8%

Europe represented roughly US$174.14 million in 2025.

Norway is the strategic center of the regional market because commercial salmon farming helped establish modern aquaculture vaccination.

Current exact-market benchmarking places Europe at 34.8% of 2025 market revenue.

Mediterranean seabass, seabream and trout create an additional vaccine market across Spain, Greece, Türkiye, Italy and neighboring countries.

Europe's strongest future opportunities are likely to involve multivalent salmon vaccines, viral disease prevention, sea-lice vaccine research and reduced antibiotic use.

Asia-Pacific - 18.4%

Asia-Pacific accounted for an estimated US$92.07 million in 2025 but should record the fastest growth through 2035.

This is where the global production footprint and vaccine revenue footprint are most misaligned.

FAO reports that Asia produced 130 million tonnes of aquaculture output in 2024, nearly three-quarters of the region's aquatic production.

Yet commercial vaccine penetration remains much lower than in salmon-producing markets.

That represents a large white-space opportunity.

Tilapia, pangasius, yellowtail, seabass and freshwater species all provide addressable markets if vaccination methods become more scalable.

Japan: High-Value Species Support Advanced Multivalent Products

Japan's vaccine opportunity is concentrated around high-value marine fish rather than the enormous farmed volumes found elsewhere in Asia.

Kyoritsu Seiyaku's aquaculture portfolio illustrates the sophistication of this market.

Its current Pishibac Injection 4 is a tetravalent inactivated vaccine for yellowtail-related fish covering multiple forms of α-haemolytic streptococcosis, vibriosis and iridovirus disease.

Its newer Pishibac Rensa α3 oil formulation protects against all three identified serotypes of α-haemolytic streptococcosis in yellowtail species.

Japan should therefore remain an important market for technically sophisticated vaccines even if overall production volume is lower than China or Southeast Asia.

India: One of the Largest Underpenetrated Opportunities

India is strategically important because aquaculture scale is substantial while vaccine penetration remains relatively low.

ICAR's July 2026 training program covered recombinant VNN antigen production, oral, immersion and injection vaccination, and immunological monitoring in Asian seabass, demonstrating increasing domestic scientific capability.

Domestic institutions have also previously transferred fish-vaccine technology for bacterial diseases to commercial manufacturers, creating a pathway between public research and industrial vaccine production.

India could therefore become one of the most important markets for affordable warm-water fish vaccines during the forecast period.

Latin America - 5.5%

Latin America represented an estimated US$27.52 million in 2025.

Its strategic importance is greater than the revenue share suggests.

Chile is one of the world's leading salmon producers and supports sophisticated vaccination programs.

Brazil has major tilapia production.

PHARMAQ's portfolio already includes salmon vaccines in Chile and tilapia products across Brazil and neighboring markets.

The region therefore supports both ends of the aquaculture vaccine spectrum: premium salmon and high-volume tropical species.

Middle East & Africa - 3.3%

Middle East & Africa generated an estimated US$16.51 million in 2025.

Commercial vaccination remains comparatively underdeveloped.

The opportunity is linked primarily to tilapia, trout and expanding intensive aquaculture projects.

The main constraints are distribution, cold-chain infrastructure, technical veterinary support and the economics of vaccinating lower-value fish.

Mass-administration technologies could materially change the region's addressable market.

Key Players

The global aquaculture vaccines competitive landscape includes Zoetis/PHARMAQ, MSD Animal Health, HIPRA, Kyoritsu Seiyaku, Elanco Animal Health, Phibro Animal Health, Tecnovax, KBNP, Kyoto Biken Laboratories, Virbac, Veterquimica and regional/autogenous vaccine manufacturers.

The current DataM page identifies Merck/MSD, Tecnovax, HIPRA, Zoetis, Phibro Animal Health, Elanco, KBNP, Kyoto Biken, Veterquimica and Virbac among the principal participants.

Competition increasingly depends on more than antigen portfolios. Species coverage, diagnostic capability, administration equipment, regulatory presence and farm-level technical support are becoming equally important.

Detailed Company Profiles

Zoetis / PHARMAQ - The Integrated Fish-Health Platform

PHARMAQ, part of Zoetis, holds one of the strongest dedicated positions in global aquaculture health.

Zoetis describes PHARMAQ as a global leader in fish health and vaccines with more than two decades serving commercial aquaculture. Its activities extend beyond biological products into vaccination equipment and diagnostic services.

The vaccine portfolio is particularly strong in salmonids.

ALPHA JECT products cover combinations of IPN, ISA, furunculosis, vibriosis, cold-water vibriosis, winter sore and pancreas disease across major salmon-producing countries.

The company is also extending outside salmon.

ALPHA JECT micro 1 Tila targets streptococcosis in tilapia, while ALPHA JECT Panga 2 addresses bacterial diseases in pangasius.

Its largest competitive advantage is integration.

PHARMAQ Fishteq supplies vaccination machinery, while PHARMAQ Analytiq provides PCR, microbiology, histopathology, water-quality and next-generation sequencing capabilities.

Zoetis' current R&D program adds another layer by developing DNA vaccines and other solutions for salmon and tilapia.

This combination allows Zoetis to compete across prevention, diagnosis and administration rather than only through vaccine manufacturing.

MSD Animal Health - Broad Vaccine Platforms Across Cold- and Warm-Water Species

MSD Animal Health has one of the industry's longest histories in fish vaccination.

The company operates across Atlantic salmon, coho salmon, trout, tilapia, marine fish, barramundi and shrimp-related health applications. Its aquaculture portfolio includes inactivated, live and DNA vaccines delivered through injection, immersion and oral routes.

Its AQUAVAC range demonstrates its warm-water presence.

AQUAVAC Irido V targets iridovirus, while AQUAVAC Strep SA and Strep Si address major streptococcal pathogens affecting commercial fish production.

MSD's strategic significance also comes from the history of salmon vaccination.

The company states that its introduction of cold-water vibriosis and furunculosis vaccines in Norwegian salmon farming dramatically reduced antibiotic use in fish feed, and it continues to develop automatic salmon-vaccination technology.

This provides MSD with a particularly strong commercial position where aquaculture producers view vaccination as part of antimicrobial-reduction strategy.

HIPRA - Building a Mediterranean Disease-Prevention Franchise

HIPRA has developed one of the clearest species- and disease-focused aquaculture vaccine portfolios in Europe.

Its ICTHIOVAC range includes products against vibriosis, pasteurellosis, Viral Nervous Necrosis, lactococcosis, tenacibaculosis, streptococcosis and yersiniosis across seabass, seabream, turbot, trout and salmon.

The company's Mediterranean positioning is particularly strong.

ICTHIOVAC VR/PD is an injectable inactivated vaccine designed to protect seabass against both vibriosis and pasteurellosis using multiple antigens.

ICTHIOVAC VNN extends that portfolio into viral disease by targeting Viral Nervous Necrosis in seabass.

HIPRA's competitive model extends beyond standard products.

The company provides autogenous vaccine services, diagnostics, aquaculture analytics and the ICTHIODose tool for calculating vaccine requirements according to species, fish size and administration route.

That integrated support gives HIPRA a strong position with Mediterranean producers managing several different bacterial and viral disease risks.

Kyoritsu Seiyaku - Japan's High-Value Marine Fish Specialist

Kyoritsu Seiyaku provides an important example of how regional aquaculture vaccine companies can build strong positions around locally valuable species.

Its focus includes yellowtail and related marine finfish, which are economically important to Japanese aquaculture.

In June 2026, the company highlighted development of Pishibac Injection Rensa α3 oil, an oil-adjuvanted product designed to protect yellowtail-related species against all three recognized serotypes of α-haemolytic streptococcosis. Kyoritsu describes the product as the first vaccine to cover all three serotypes.

The company's Pishibac Injection 4 demonstrates an even broader multivalent strategy. The inactivated vaccine covers Type I and II α-haemolytic streptococcosis, J-O-3 vibriosis and iridovirus disease in applicable yellowtail species.

Kyoritsu's competitive strength lies less in global species coverage than in deep adaptation to Japanese disease epidemiology.

That model is increasingly relevant to the wider aquaculture vaccine market because pathogen profiles differ markedly between species and regions.

Strategic Takeaways

Salmon Will Remain the Revenue Anchor, but Warm-Water Fish Will Drive Expansion

Salmon provides the most mature vaccination economics. The larger incremental opportunity comes from adapting vaccination to tilapia, pangasius and other species where farm populations are much larger but per-fish values are lower.

Oral Vaccines Could Expand the Market Rather Than Simply Shift Market Share

If feed-based immunization becomes consistently effective, farms currently unable to justify individual injections can become new vaccine customers.

Bacterial Vaccines Will Remain Largest, but Viral Vaccines Will Capture More R&D Value

Commercial bacterins already address a wide disease range. DNA and recombinant technologies are increasingly being directed toward difficult viral pathogens.

Vaccination Equipment Is Becoming Part of the Product

Injection at commercial scale requires accuracy and throughput. Automation therefore increases the commercial moat around leading vaccine franchises.

Diagnostics and Vaccines Are Converging

A producer increasingly needs to know which pathogen and strain is present before selecting the strongest prevention strategy. This favors companies combining diagnostics, vaccine portfolios and farm-support services.

Autogenous Vaccines Will Gain Importance as Disease Surveillance Improves

Better molecular diagnostics identify strain differences that standard commercial vaccines may not cover, increasing demand for farm- and region-specific biologicals.

Asia-Pacific Represents the Largest Revenue White Space

Asia dominates global aquaculture production but not aquaculture-vaccine revenue. Closing that gap requires products designed around tropical species, local disease epidemiology and lower-cost mass administration.

Market Restraints

The greatest market constraint is the economics of administering vaccines to lower-value fish.

An injection strategy that is rational for a premium salmon may be uneconomic for millions of smaller tropical fish.

Regulatory approval is also demanding.

Aquaculture vaccines must demonstrate safety and efficacy in species living within open or semi-open biological environments.

Species diversity further complicates commercialization.

Aquaculture involves vastly more commercially farmed species than poultry or swine production. A vaccine developed for Atlantic salmon cannot automatically serve tilapia or seabass.

Disease diversity adds another layer.

Different farms can encounter distinct strains, making protection less predictable.

Cold-chain distribution remains a major constraint in developing aquaculture markets.

Finally, the immune biology of aquatic species creates technical challenges, particularly for crustaceans. WOAH notes that conventional adaptive immune vaccine concepts do not translate straightforwardly to crustaceans and molluscs because their immune systems differ significantly from finfish.

This is why the current commercial market remains overwhelmingly finfish-focused.